Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY4086940 in obesity and type 2 diabetes mellitus (T2DM) (11 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Events. Started Apr 2025; status: completed.
02
Drugs
LY4086940
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06945419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945419.